Nutritional science

CorMedix Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Donnerstag, Mai 9, 2024
FDA, Sale, CMS, ESRD, Investment, Drug, Risk, Research, TPN, Patient, Nutritional science, Eastern Time Zone, Marketing, HCPCS, Pharmaceutical industry

BERKELEY HEIGHTS, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the first quarter ended March 31, 2024 and provided an update on its business.

Key Points: 
  • BERKELEY HEIGHTS, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the first quarter ended March 31, 2024 and provided an update on its business.
  • The TDAPA program currently provides for five years of additional payment reimbursement beyond the ESRD bundled rate to outpatient providers.
  • Operating expenses in the first quarter 2024 were $15.9 million, compared with $11.0 million in the first quarter of 2023, an increase of approximately 44%.
  • The management team of CorMedix will host a conference call and webcast today, May 9, 2024, at 8:30am Eastern Time, to discuss recent corporate developments and financial results.

RYAM Announces Improved First Quarter 2024 Results

Retrieved on: 
Dienstag, Mai 7, 2024
Chemicals, Plastics, Retail, Alternative Energy, Energy, Manufacturing, Alternative Vehicles, Fuels, Pharmaceutical, Forest Products, Agriculture, Natural Resources, Other Manufacturing, Automotive, Food, Beverage, Packaging, Health, Corporation, Sale, Paperboard, Average cost, Cellulose, GRAS, ERP, Conference, Public expenditure, Operating cost, Adjustment, Nutritional science, USDOC, Fine chemical

Operating results improved $70 million primarily due to the $62 million non-cash asset impairment recorded in the fourth quarter.

Key Points: 
  • Operating results improved $70 million primarily due to the $62 million non-cash asset impairment recorded in the fourth quarter.
  • Included in non-operating other income in the quarter ended March 30, 2024 was a $1 million impact from favorable foreign exchange rates in the current quarter.
  • EBITDA is expected to decrease in the second quarter of 2024 compared to the first quarter of 2024 due to the annual planned maintenance outage at Jesup, but stronger than the second quarter of 2023.
  • Paperboard prices in 2024 are expected to remain relatively stable compared to the first quarter of 2024, while sales volumes are expected to improve due to improved customer demand.

Global Functional Dyspepsia Drug Market to reach a valuation of US$ 16.4 billion by 2034, Future Market Insights, Inc. Projection

Retrieved on: 
Mittwoch, Mai 1, 2024
Gastroenterology, Transplant, Acupuncture, Indigestion, Research, Laboratory, Probiotic, Abbott Laboratories, Herbal, Therapy, Patient, Tissue engineering, Enzyme inhibitor, Regenerative medicine, Collaboration, Market, Diagnosis, Antacid, Drug development, Regeneration, Ageing, Investment, Nutritional science, Pharmaceutical industry

NEWARK, Del., May 1, 2024 /PRNewswire/ -- The global functional dyspepsia drug market will reach a valuation of US$ 10.3 billion in 2024, attributed to factors such as increasing geriatric population. The trend is set to create new opportunities for the market, leading to a projected CAGR of 4.8% between 2024 and 2034, and reaching a total valuation of approximately US$ 16.4 billion by 2034.

Key Points: 
  • NEWARK, Del., May 1, 2024 /PRNewswire/ -- The global functional dyspepsia drug market will reach a valuation of US$ 10.3 billion in 2024, attributed to factors such as increasing geriatric population.
  • Collaboration between pharmaceutical companies, academic institutions, and research organizations fosters innovation in functional dyspepsia drug development.
  • Key Takeaways from the Market Study:
    Global functional dyspepsia drug market was valued at US$ 9.7 billion in 2023.
  • The functional dyspepsia drug market is characterized by a diverse array of pharmaceutical companies, research institutions, and healthcare organizations striving to develop and commercialize innovative treatments for functional dyspepsia.

Global Functional Dyspepsia Drug Market to reach a valuation of US$ 16.4 billion by 2034, Future Market Insights, Inc. Projection

Retrieved on: 
Mittwoch, Mai 1, 2024
Gastroenterology, Transplant, Acupuncture, Indigestion, Research, Laboratory, Probiotic, Abbott Laboratories, Herbal, Therapy, Patient, Tissue engineering, Enzyme inhibitor, Regenerative medicine, Collaboration, Market, Diagnosis, Antacid, Drug development, Regeneration, Ageing, Investment, Nutritional science, Pharmaceutical industry

NEWARK, Del., May 1, 2024 /PRNewswire/ -- The global functional dyspepsia drug market will reach a valuation of US$ 10.3 billion in 2024, attributed to factors such as increasing geriatric population. The trend is set to create new opportunities for the market, leading to a projected CAGR of 4.8% between 2024 and 2034, and reaching a total valuation of approximately US$ 16.4 billion by 2034.

Key Points: 
  • NEWARK, Del., May 1, 2024 /PRNewswire/ -- The global functional dyspepsia drug market will reach a valuation of US$ 10.3 billion in 2024, attributed to factors such as increasing geriatric population.
  • Collaboration between pharmaceutical companies, academic institutions, and research organizations fosters innovation in functional dyspepsia drug development.
  • Key Takeaways from the Market Study:
    Global functional dyspepsia drug market was valued at US$ 9.7 billion in 2023.
  • The functional dyspepsia drug market is characterized by a diverse array of pharmaceutical companies, research institutions, and healthcare organizations striving to develop and commercialize innovative treatments for functional dyspepsia.

NBPure Launches Clean, Gut-Nourishing, Family-Friendly Electrolyte Drink Mix With Influencer @EarthyAndy

Retrieved on: 
Mittwoch, Mai 1, 2024
Calcium, Magnesium, Health, GMO, Partnership, Electrolyte, Water, Methyl group, Potassium, Sodium, Probiotic, B-12, Absorption, Inulin, Nutritional science

The product, Earthy Andy Hawaiian Hydration, is a clean, gut-nourishing, family-friendly, electrolyte hydration drink mix for health-minded adults and kids.

Key Points: 
  • The product, Earthy Andy Hawaiian Hydration, is a clean, gut-nourishing, family-friendly, electrolyte hydration drink mix for health-minded adults and kids.
  • Earthy Andy Hawaiian Hydration is made with natural ingredients and contains no sugar or artificial flavors, dyes, or sweeteners.
  • Andrea Hannemann, a mother of four children ages 1 to 15, is passionate about maintaining her family's health and wellness.
  • "Our new Hawaiian Hydration electrolyte drink mix is pure and good for you, and it tastes amazing thanks to the natural whole food flavors we mix in."

MD Logic Health® Introduces Their New Low Molecular Bioactive Colostrum

Retrieved on: 
Dienstag, April 30, 2024
Sale, Digestion, Protein, Solubility, Pinnacle, Milk, Cytokine, MD, Logic, Probiotic, Peptide, Colostrum, Immunity, Absorption, Nutritional science, Fats, Dairy

MIAMI, April 30, 2024 /PRNewswire-PRWeb/ -- In an era where gut health is paramount, MD Logic Health® has once again raised the bar with the introduction of its Low Molecular Bioactive Colostrum), a new pinnacle in health supplements for superior gut health and overall well-being. Known for their unwavering dedication to excellence and innovation, MD Logic Health®'s latest formulation offers unparalleled potency, purity, and efficacy.

Key Points: 
  • MD Logic Health® raises the bar in gut health innovation with its new Low Molecular Bioactive Colostrum, offering unmatched potency and efficacy.
  • - Wesley Ramjeet, CEO of MD Logic Health®
    As the market's demand for effective gut health solutions intensifies, MD Logic Health® delivers a compelling answer with its Low Molecular Bioactive Colostrum.
  • The Low Molecular Bioactive Colostrum is sourced from all-natural, hormone-free grass-fed cattle maintained on a carefully selected, nutrient-rich diet.
  • MD Logic Health®'s Low Molecular Bioactive Colostrum is a revolution in wellness, designed to meet the needs of modern health-conscious consumers.

Mother's Day in Hollywood - a Distinctive Tradition

Retrieved on: 
Dienstag, April 23, 2024
Foam, Honey, Cream, Family, Coffee, Shakes, PJS, Coconut oil, DBL, CHC, Mineral, Pet food, Life, DAX, Pet, Olympia-Werke, Melting, Joy, Mother's Day, Nutritional science

LOS ANGELES, April 23, 2024 /PRNewswire/ -- Distinctive Assets, the LA-based entertainment marketing company credited with launching the promotional craze of celebrity swag twenty-five years ago, will once again be producing and distributing its annual "Mother's Day in Hollywood" celebrity gift boxes. Distinctive Assets will pamper twenty-five of the world's most famous moms with a broad array of fabulous gifts that are innovative, unique and useful! All-star mommies on this year's gift list include Blake Lively, Keke Palmer, Kaley Cuoco, Halle Bailey, Emily Vancamp, Uzo Aduba, Ali Wong, Grace Gummer, Naomi Osaka, Jordin Sparks, Meghan Trainor, Jennifer Garner, Rumer Willis and Greta Gerwig (among others).

Key Points: 
  • LOS ANGELES, April 23, 2024 /PRNewswire/ -- Distinctive Assets, the LA-based entertainment marketing company credited with launching the promotional craze of celebrity swag twenty-five years ago, will once again be producing and distributing its annual "Mother's Day in Hollywood" celebrity gift boxes.
  • Distinctive Assets will pamper twenty-five of the world's most famous moms with a broad array of fabulous gifts that are innovative, unique and useful!
  • "Mother's Day is such a wonderful opportunity to acknowledge those tackling one of the most challenging jobs around: motherhood!
  • The moms on our list inspire us through their work, and we hope to pamper them while supporting their parenting journey," says Distinctive Assets' founder and noted gift expert Lash Fary.

Royal Canin Unveils Expansion to Gastrointestinal Portfolio, Announces Five New Diets

Retrieved on: 
Dienstag, April 16, 2024
Psyllium, Protein, Pet, Veterinarian, Cat, Mars, Science, Diet, Mars, Incorporated, Dog, Royal Canin, Nutritional science, Animal feed

ST. CHARLES, Mo., April 16, 2024 /PRNewswire/ -- ROYAL CANIN® U.S., a division of Mars, Incorporated and leader in pet health nutrition, has announced an expansion to its Veterinary Gastrointestinal (GI) portfolio. Gastrointestinal issues are the 3rd and 4th most common issue in cats and dogs that prompt a veterinary visit, and tailored nutrition can have a significant impact in nourishing and supporting their GI tract and microbiome.1,2

Key Points: 
  • ST. CHARLES, Mo., April 16, 2024 /PRNewswire/ -- ROYAL CANIN® U.S., a division of Mars, Incorporated and leader in pet health nutrition, has announced an expansion to its Veterinary Gastrointestinal (GI) portfolio.
  • ROYAL CANIN® Gastrointestinal Low Fat Small Dog is formulated for the nutritional management of small dogs needing a fat-restricted diet.
  • All Royal Canin veterinary-exclusive Gastrointestinal diets are formulated to support the intestinal microbiome, due to the inclusion of highly digestible protein and a robust fiber blend inclusive of prebiotic fibers.
  • Talk to your veterinarian to learn more about Royal Canin Gastrointestinal diets.

Try Maggie Q's ActivatedYou Morning Complete to Help Minimize Stress for Stress Awareness Month

Retrieved on: 
Donnerstag, April 11, 2024
Spend, Nature, Glass, Health, Gymnema, Nutritional science, Water, Life, Yoga, Completeness, Mental health, Happiness, Mindfulness, Probiotic, Metabolism, LOS, Nutrient, Antioxidant, Anxiety, Growth, Meditation, Dietary supplement

LOS ANGELES, April 11, 2024 /PRNewswire/ -- Stress Awareness Month is observed annually in April to raise awareness about the causes and effects of stress, as well as to provide individuals with tools and resources to manage stress effectively. It serves as a reminder to prioritize mental health and well-being in our daily lives.

Key Points: 
  • Maggie Q recommends ActivatedYou® Morning Complete® , a powerful daily wellness drink featuring a custom-selected blend of nutrients designed to help "rev up" your metabolism, keep your spirit lifted, and provide the boost of energy needed to tackle any task.†*
    What is ActivatedYou Morning Complete?
  • Other blends featured in Morning Complete include probiotics, prebiotics, antioxidants, green superfoods, metabolic support, and blends for cellular function and liver support.
  • Maggie Q's ActivatedYou suggests mixing Morning Complete with 8oz of water or iced green tea.
  • ActivatedYou Morning Complete can be purchased from the official ActivatedYou website .

Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition

Retrieved on: 
Freitag, April 5, 2024
Choline, Plasma, Liver, Nutritional science, Route of administration, Liver disease, Steatosis, Short bowel syndrome, Metabolism, Patient, Choline chloride, Cancer, ESPEN, Parenteral nutrition, Adolescence, Liver injury, Hepatology, Tubing (recreation), Fibrosis, Guideline, Society, Therapy, Copenhagen University Hospital, Safety, Pharmacokinetics, PN, FDA, ASPEN, Rigshospitalet, Food, Feeding tube, Extractive metallurgy

IV Choline Chloride has the potential to become the first FDA-approved IV formulation of choline for the 40,000 PN patients in the U.S.

Key Points: 
  • IV Choline Chloride has the potential to become the first FDA-approved IV formulation of choline for the 40,000 PN patients in the U.S.
  • The Company plans to advance the development of IV Choline Chloride as a source of choline for adult and adolescent patients on long-term PN.
  • The FDA has granted IV Choline Chloride Orphan Drug Designation for the prevention of choline deficiency in PN patients.
  • “We look forward to advancing the clinical development of IV Choline Chloride, which we believe has the potential to become the first FDA approved IV choline therapy for patients dependent on PN.